Organization
CHU Dijon
3 abstracts
Abstract
Very long-term follow-up of rituximab maintenance in young patients with mantle cell lymphoma included in the LYMA trial, a LYSA study.Org: Institut Curie, Saint Cloud, France, Hemato-oncology, IUCT-Oncopole Toulouse, Department of Hemagology, Centre François Magendie,
Abstract
Blood baseline neutrophil count to predict bevacizumab efficacy in glioblastoma.Org: Georges-Francois Leclerc Cancer Center, Georges François Leclerc Cancer Center – UNICANCER, Dijon, France, CHU Dijon, Centre GF Leclerc, University Hospital (CHU) - Department of Medical Oncology,
Abstract
Phase 3 randomized study of isatuximab (Isa) plus lenalidomide and dexamethasone (Rd) with bortezomib versus isard in patients with newly diagnosed transplant ineligible multiple myeloma (NDMM TI).Org: Université de Poitiers et Centre Hospitalier Universitaire de Poitiers, INSERM U1313 and CIC 1082, Poitiers, France, Hôpital Haut Leveque, University Hospital, Pessac, France, ECSTRA, Centre de Recherche en Epidémiologie et Statistiques, INSERM UMR 1153, Paris, France, Lille University Hospital, Lille, France, CHU de Toulouse, IUCT-O, Université de Toulouse, UPS, Service d’Hématologie, Toulouse, France,